Goldman Sachs Group Inc. Takes $673,000 Position in Monopar Therapeutics Inc. $MNPR

Goldman Sachs Group Inc. bought a new position in Monopar Therapeutics Inc. (NASDAQ:MNPR) in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 18,480 shares of the company’s stock, valued at approximately $673,000. Goldman Sachs Group Inc. owned approximately 0.30% of Monopar Therapeutics as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in the business. Jane Street Group LLC bought a new stake in Monopar Therapeutics in the first quarter worth approximately $377,000. OMERS ADMINISTRATION Corp bought a new stake in Monopar Therapeutics in the first quarter worth approximately $328,000. Affinity Asset Advisors LLC bought a new stake in Monopar Therapeutics in the first quarter worth approximately $2,257,000. AlphaQuest LLC bought a new stake in Monopar Therapeutics in the first quarter worth approximately $44,000. Finally, Gerber LLC bought a new stake in Monopar Therapeutics in the first quarter worth approximately $204,000. 1.83% of the stock is owned by institutional investors.

Monopar Therapeutics Trading Up 7.9%

NASDAQ MNPR opened at $73.04 on Thursday. The company has a fifty day simple moving average of $43.25 and a 200 day simple moving average of $38.70. The company has a market cap of $450.66 million, a P/E ratio of -21.93 and a beta of 1.20. Monopar Therapeutics Inc. has a 1 year low of $4.12 and a 1 year high of $74.00.

Monopar Therapeutics (NASDAQ:MNPR) last posted its quarterly earnings data on Tuesday, August 12th. The company reported ($0.35) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.47) by $0.12. Equities research analysts forecast that Monopar Therapeutics Inc. will post -1.65 EPS for the current fiscal year.

Insider Buying and Selling at Monopar Therapeutics

In other Monopar Therapeutics news, Director Christopher M. Starr sold 16,800 shares of the stock in a transaction on Monday, July 14th. The shares were sold at an average price of $40.00, for a total value of $672,000.00. Following the completion of the sale, the director directly owned 5,173 shares of the company’s stock, valued at $206,920. This represents a 76.46% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Chandler Robinson sold 16,800 shares of the stock in a transaction on Monday, July 14th. The shares were sold at an average price of $40.00, for a total transaction of $672,000.00. Following the completion of the sale, the chief executive officer directly owned 73,472 shares of the company’s stock, valued at approximately $2,938,880. This trade represents a 18.61% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 42,504 shares of company stock valued at $1,700,160 in the last ninety days. Company insiders own 20.50% of the company’s stock.

Analyst Ratings Changes

MNPR has been the subject of several recent research reports. Lake Street Capital initiated coverage on shares of Monopar Therapeutics in a research report on Tuesday. They issued a “buy” rating and a $106.00 target price for the company. Chardan Capital reissued a “buy” rating and issued a $60.00 target price on shares of Monopar Therapeutics in a research report on Tuesday, September 16th. Raymond James Financial started coverage on shares of Monopar Therapeutics in a research report on Tuesday, September 2nd. They issued a “strong-buy” rating and a $80.00 target price for the company. HC Wainwright started coverage on shares of Monopar Therapeutics in a report on Tuesday, August 26th. They set a “buy” rating and a $70.00 price objective for the company. Finally, Oppenheimer started coverage on shares of Monopar Therapeutics in a report on Wednesday, September 3rd. They set an “outperform” rating and a $77.00 price objective for the company. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and one has issued a Hold rating to the company’s stock. According to MarketBeat, Monopar Therapeutics has a consensus rating of “Buy” and a consensus target price of $75.56.

Monopar Therapeutics Profile

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.